Hormone therapyFDA-approvedSecond-line
Enzalutamide
How it works
Blocks the action of testosterone on prostate cancer cells, preventing them from growing.
Cancer types
Prostate Cancer— All patients
Efficacy
Enzalutamide has been shown to significantly improve overall survival and delay disease progression in patients with advanced prostate cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Enzalutamide and PDS01ADC in Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Biomarker for Prostate Cancer Resistance to Enzalutamide Identified | Prostate Cancer | lab-study | — | Source → |
| Study of Prostate Cancer Treatment with Apalutamide or Enzalutamide | Prostate Cancer | phase-3 | — | Source → |
| Study of Talazoparib and Enzalutamide in Men with Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Evaluating Pembrolizumab and Enzalutamide in Metastatic Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Researchers Identify New Target to Overcome Enzalutamide Resistance in Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| Enzalutamide Resistance in Prostate Cancer Linked to KCNN4 | Prostate Cancer | lab-study | — | Source → |
| ZNF711 Contributes to Resistance to Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
| Combination Therapy Shows Delayed Survival Benefit in Prostate Cancer | Prostate Cancer | phase-3 | Significant survival benefits were observed after 60 months, with RMST differences of 4.34 months (95% CI, 0.49-8.19, p = 0.03) at 60 months and 6.25 months (95% CI, 1.56-10.95, p = 0.01) at 72 months. | Source → |
| Enzalutamide Resistance in Prostate Cancer Linked to UFL1 Deficiency | Prostate Cancer | lab-study | — | Source → |
| Enzalutamide Monotherapy for Prostate Cancer | Prostate Cancer | phase-3 | The 5-year probability rate of overall survival was 89.5% for enzalutamide monotherapy vs 87.2% for leuprolide alone. | Source → |
| Genetic Link to Abiraterone Dosage Identified in Prostate Cancer Study | Prostate Cancer | phase-3 | — | Source → |
| Early Docetaxel and Enzalutamide for Prostate Cancer: New Insights | Prostate Cancer | phase-3 | Among those assigned no enzalutamide, OS was longer with the planned use of early docetaxel (HR 0.90, 95% CI 0.82-0.98), especially in high-volume disease. | Source → |
| Abiraterone and Enzalutamide Show Similar Outcomes in Prostate Cancer | Prostate Cancer | observational | Median overall survival was 36.2 months for both abiraterone and enzalutamide. | Source → |
| Researchers Identify New Pathway in Prostate Cancer Resistance | Prostate Cancer | lab-study | — | Source → |
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-3 | Treatment with enzalutamide + ADT significantly prolonged the primary endpoint of radiographic progression-free survival (HR [95% confidence interval, CI]: 0.54 [0.32-0.93], p = 0.03) compared with darolutamide + ADT. | Source → |
| Enzalutamide May Offer Better Survival for Prostate Cancer Patients | Prostate Cancer | observational | Enzalutamide-treated patients had longer overall survival in the first-line setting (HR: 0.84) and the second-line setting (HR: 0.88). | Source → |
| OPRK1 linked to resistance to prostate cancer treatment | Prostate Cancer | lab-study | — | Source → |
| Researchers Identify Cells That May Contribute to Prostate Cancer Resistance | Prostate Cancer | lab-study | — | Source → |
| Researchers Identify New Gene Linked to Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.